本帖最后由 老马 于 2012-1-13 21:20 编辑
/ M# h) N/ x p# k! `
! G# Z7 E# C6 P5 h' r爱必妥和阿瓦斯丁的比较
/ f) l2 w4 I% H8 b, R$ L7 ?
8 h/ m. Z- [" A/ S0 R' v- l9 I- m
http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
: ~, ]2 Z0 u/ J8 F
' B) [0 U L2 Q; t7 h" Z8 ^# O- L% g
% `. g G" P# M6 D+ Q7 t( K' hhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
$ D5 \% A: O e==================================================3 n# n- s7 Z, `4 g& L
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)$ w4 @) L3 w7 O+ x8 y; v6 a" m
Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
) C. l8 Q3 e+ O$ t) ?$ }Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
; q+ C% N# ?, i" g2 F1 s2 y9 _
|